Brought to you by 
Lilly signs diabetes option agreement with Alize Pharma
05 Mar 2010
Executive Summary
Eli Lilly has paid an undisclosed sum up front for an exclusive option to license a diabetes project from Alize Pharma (metabolic diseases and cancer). The companies will initially perform joint development; terms of the option exercise were not disclosed.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly signs diabetes option agreement with Alize Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice